Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older